SYNACT PHARMA

Synact Pharma AB

A new medicine to treat inflammatory diseases

Jeppe Øvlesen, MBA
CEO

Thomas Jonassen, MD
CSO

SYNACT PHARMA – OVERVIEW

- Synact Pharma AB listed at Aktietorget in July 2016
- Ticker SYNACT; Aktietorget
- Introduction price at 6.40 SEK per share
- Current (March 6) 14.35 SEK per Share
- Marked cap (March 6) of 178.0 SEK



SYNACT PHARMA TEAM



Jeppe Øvli Øvlesen, MBA

- CEO
- > 15 years of CEO experience
- Investor and founding Board Member at a number of Biotech/Medtech companies
- Co-founder of TXP Pharma
- Former CFO & VP BD of Action Pharma

Thomas Jonassen , MD

- Co-founder and CSO,
- Member, Board of Directors
- Associate Professor, KU in Denmark
- Honorable Professor, WHRI, United Kingdom
- Co-founder of TXP Pharma
- Co-founder and former CSO of Action Pharma

Henrik Stage, MsC

- CFO
- Former CEO and CFO at Santaris Pharma
- >25 years experience from Biotech and financial industry

Torbjørn Bjerke, MD

- Chairman, Board of Directors
- Co-founder and Chairman in TXP PHarma
- > 25 years track record from Pharma industry as Head R&D and CEO.
- Co-founder of Action Pharma A/S
- Member, BoD for DBV Technologies

Lars Adelsson

- Member, Board of Directors
- Former GM, GlaxoSmithKline Sweden; Austria
- Former CEO, Medivir
- Member, BoD for Evolan Pharma; Swedish Pharmaceutical Manufacturers Association

Charlotte Edenius, MD, PhD

- Member, Board of Directors
- Former Executive Vice President for R&D, Medivir AB; Senior Vice President for R&D Orexo AB, Vice President and CSO Biolipox AB and various roles AstraZeneca Clinical R&D
- Member, BoD for Kancera, Immunicum and Gesynta

MELANOCORTIN THERAPY – RECENT DEALS

SYNACT PHARMA

2012	2013	2014	2015	2017
Action Pharma´s AP214 program Phase 2 Deal value: €105m	TXP Pharma´s peptide program Deal value: €95m	Questor including ACHTAR gel Deal value: €5.7b	Merck cortico-tropin products Deal value: €70m	Palatins Recynda program (Phase 3) Deal value: €400m

Also worth mentioning is Rhythm Pharmcaeuticals - targeting the MC4r in POMC defiance Obesity patients- who recently went public-current market cap: in excess of 700 M US$

All specialized programs focused on peptide derived therapy

SYNACT PHARMA – OVERVIEW

SYNACT PHARMA

- Main strategy is to develop lead compound AP1189 into Phase II clinical development in inflammatory joint diseases
- Investigate opportunities in additional indications with the possibility to setup development path in second indication
- Strong IP position
- Business model to sell or out-license the project to bio pharma or big biotech
- Current market for lead indication is several Bn $ annually and growing

SYNACT PHARMA - TODAY

- AP1189 SynAct Pharma´s lead project is in clinical development for active joint disease – ie rheumatoid and psoriatic arthritis
- Status from ongoing Phase 1 studies shows
  - Well tolerated with attractive safety profile
  - Promising pharmacokinetics profile, supporting once daily oral dosing
  - Tablet for once daily dosing is currently tested in repeat dosing regiment
- Filing of Phase IIa clinical application is scheduled for Q2 2018

- The potential of the compound in additional high-value indications -includes systemic lupus (SLE), Intestinal bowel disease (IBD), multiple Sclerosis (MS) and nephrotic syndrome (NS)- is exploited in ongoing experimental studies.

RESOLUTION OF INFLAMMATION: A NEW THERAPEUTIC FRONTIER

SYNACT PHARMA



- Resolution therapy holds promise to correct overshooting/ongoing inflammation typical of several pathological settings.

AP1189- STIMULATION OF MELANOCORTIN RECEPTORS ON WHITE CELLS -

SYNACT PHARMA

The inflammatory proces:



- **Release of Inflammatory mediators**
- **Infiltration with white cells**

+ AP1189



Cells are cleared

Inflammation resolves

AP1189 stimulates melanocortin-receptors and facilitates thereby resolution of inflammation

MELANOCORTIN DERIVED THERAPY- CURRENT MARKED

SYNACT PHARMA

- ACTH (ACHTAR gel) is a potent anti-inflammatory compound that mediates it anti-inflammatory effects through melanocortin receptor activation
- Current annual sale of around $ 1.25 Bn -





Source: Mallinckrodt Pharmaceuticals Investor Briefing October 4, 2017

MELANOCORTIN DERIVED THERAPY-

SYNACT PHARMA

- ACTH (ACHTAR gel) has potent anti-inflammatory effects in a variety of severe autoimmune and inflammatory disorders

- Two-way mode of action:
    1. Melanocortin receptor activation (non-selective)
    2. Release of steroid hormones
- Route of administration: subcutaneous injections



Limited for <u>difficult to treat patients</u>, due to side-effect profile with unwanted steriod hormone effects and stimulation of dermal pigmentation

AP1189 has the beneficial therapeutic effects related to melanocortin receptor stimulation- AP1189 does not have steriod hormone effects and does not induce dermal pigmentation – in addition AP1189 is oral available

AP1189- DATA FROM PHASE I

SYNACT PHARMA

- Dosing completed in 64 healthy volunteers (male as well as post menopausal women)
- In general well tolerated up to highest dose level, where peak exposures reached > 10 times the efficacious concentrations
- Long elimination half life support once daily administration
- Repeat dosing with newly developed tablet is ongoing

Compound present in blood 24 hours following dosing



Anticipated peak level needed for therapeutic effect

MARKTET OPPORTUNITY IN ACTIVE JOINT DISEASE

SYNACT PHARMA

- PsA and RA patients present with comparable clinical symptoms and respond to similar treatment modalities, despite different etiologies of disease
- Both the RA and PsA treatment markets are dominated by high priced biologics providing feasibility for novel oral entrants with moderate-high price levels
- Both the RA and PsA markets are growing at double digit rates due to aging populations and novel market entrants
- The RA market is roughly 10x larger than the PsA market in $ terms

AP1189 – POSITIONING IN ACTIVE JOINT DISEASE

SYNACT PHARMA

- Patients with active joint disease are currently treated with Methotrexate (MTX)
- Around 40% of these patients have an inadequate response to MTX-
- Next line compounds are expensive and often associated with unwanted side effects
- Even among patients treated with the expensive biologics, up to 30% of the patients still suffer from inadequate treatment effects

A compound given as early add-on to MTX that could reduce the need for second line treatment and/or reduce the dose levels of MTX to option remission of symptoms would have major impact in active joint disease

AP1189 UNIQUE SELLING POINTS

SYNACT PHARMA

AP1189

- excellent oral PK and can be developed as a once-daily tablet formulation
- very well tolerated in ongoing Phase 1 clinical testing
- robust efficacy in preclinical models of arthritis, IBD and peritonitis
- Ongoing studies evaluate additional development opportunities
- potential to be a first-in-class treatment option for inflammatory diseases with big medical needs

AP1189- DEVELOPMENT OVERVIEW

SYNACT PHARMA

Phase I	• Part 1 and 2 completed • Part 3 to be completed followed by reporting
Phase II	• Preparation of Phase II Clinical trial in lead indication • Trial application to be filed in Q2 • Study to be initiated in Q3-
Pre-Clinical	• Testing of compound in additional disease models • Evaluate potential new business opportunities emerged from new data

Continuous business development discussions with potential partners

SYNACT PHARMA

CEO, Jeppe Øvlesen
joo@synactpharma.com
Tel.: + 45 2844 7567

CFO, Henrik Stage
hs@synactpharma.com
Tel.: + 45 4026 0900

www.synactpharma.com